Supplementary Table 1. Patient demographic

	Age (years)	Sex	THV (mm)	Annulus (mm^2)	%OS	LVOT (mm^2)	Inflation volume	AR post-TAVI	RBC transfusion	AR at follow-up	Max LDH (IU/L)	Management	Status*
Case 1	Mid-80s	Male	23	395	+2.7%	313	Nominal (17 ml)	Moderate	+	Moderate	1,367	Redo (POD 80)	Death (POD 89)
Case 2	Early-80s	Female	20	346	-5.2%	287	Nominal (11 ml)	Mild	-	Moderate to Severe	1,289	Redo (POD353)	Alive (POD 373)
Case 3	Late-80s	Female	26	511	+1.6%	459	-1 ml (22 ml)	Moderate-Severe	+	Moderate to Severe	1,624	Watch	Alive (POD 355)
Case 4	Early-80s	Female	20	324	+1.2%	269	Nominal (11 ml)	Trivial	-	Mild to Moderate	1,206	BAV (POD 84)	Alive (POD 247)
Case 5	Early-90s	Female	20	351	-6.6%	303	+1 ml (12 ml)	Mild	+	Mild	512	Watch	Alive (POD 188)
Case 6	Early-70s	Male	26	517	+0.4%	454	Nominal (23 ml)	Trivial	+	Mild to Moderate	1,636	Watch	Alive (POD 107)

THV, transcatheter heart valve; OS, oversizing; LVOT, left ventricular outflow tract; AR, aortic regurgitation; RBC, red blood cell; LDH, lactate dehydrogenase; HFH, hospitalization for heart failure; POD, postoperative day; BAV, balloon aortic valvuloplasty; PVE, prosthetic valve endocarditis.

*As of November 6, 2024.